APA (7th ed.) Citation

M, T., JR, A., L, A., AR, H., J, P., V, T., . . . D, C. (2023). Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): A randomised, double-blind, placebo-controlled phase 3 trial. Critical care (London, England), 27(1), 9. https://doi.org/10.1186/s13054-022-04205-8

Chicago Style (17th ed.) Citation

M, Trøseid, et al. "Efficacy and Safety of Baricitinib in Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-blind, Placebo-controlled Phase 3 Trial." Critical Care (London, England) 27, no. 1 (2023): 9. https://doi.org/10.1186/s13054-022-04205-8.

MLA (9th ed.) Citation

M, Trøseid, et al. "Efficacy and Safety of Baricitinib in Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-blind, Placebo-controlled Phase 3 Trial." Critical Care (London, England), vol. 27, no. 1, 2023, p. 9, https://doi.org/10.1186/s13054-022-04205-8.